drugset / Trial / NCT00988312
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.
Timeline
- Start
- 2002-03
- Primary completion
- 2004-02
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous idiotype-protein pulsed dendritic cells | Vaccine | — | Subcutaneous |